Stephen V Liu, MD
@StephenVLiu
Director of Thoracic Oncology & Developmental Therapeutics @Georgetown @LombardiCancer; Host @IASLC Podcast; Chair #DCLung24 #TexasLung24 #HereWeGo
ID:377425889
https://www.medstarhealth.org/doctors/stephen-liu-md 21-09-2011 15:17:53
17,3K Tweets
24,1K Followers
3,0K Following
Follow People
The ongoing development of Nuvalent’s zidesamtinib (NVL-520) is an important step forward for our ROS-1 #lungcancer & #cancer community. Here Dr Stephen V Liu, MD highlights the great promise & limited low grade toxicities.
onclive.com/view/dr-liu-on…
#lcsm ROS1ders UK The ROS1ders, Inc.
Looking forward to hearing more about these studies.
'Dr Stephen V Liu, MD Previews ASCO 2024 Lung Cancer Data'
onclive.com/view/dr-liu-pr… via @onclive
In this virtual tumor board episode of #LungCancerConsidered , host Stephen V Liu, MD leads a discussion about the management of metastatic PD-L1 low #NSCLC . W/guests Apar Kishor Ganti, from University of Nebraska Medical Center, & Dr. Sze Wai Chan, from the Sandton Oncology Centre. Listen Now: bit.ly/PDL1NSCLC24 #LCSM
Report of real-world 5-year survival with 1L pembrolizumab in PD-L1 high NSCLC Clinical Lung Cancer. With median f/u 60.5m, median OS 19.2m, 5y OS rate 25.1%. Also noted 33% received subsequent therapy. Great real world collaboration with Dr. Vamsi Velcheti, MD MBA.
clinical-lung-cancer.com/article/S1525-…
Looking forward to discussing Targeted Therapy in NSCLC at the UPMC Hillman Cancer Center Pittsburgh Annual Oncology Symposium on Friday August 23, 2024. Great lung sessions with Drs. Liza Villaruz, Mark Socinski, Tim Burns, and Sudhamshi Toom. Hope to see you there!
Electronic nose tech uses exhaled volatile organic compounds and is being studied as a way to detect early stage lung cancers. Report of E-nose performance in pts with suspected stage I NSCLC JTO & JTO CRR shows promise. Can this complement CT screening?
jto.org/article/S1556-…
Outcomes with first-line osimertinib in 37 pts with rare atypical #EGFR exon 19 or compound mutations in #JTOCRR JTO & JTO CRR from Dr. Susan Combs Scott, MD Tia Cheunkarndee. RR 76%, median PFS 13m, time to discontinuation 22m, mOS 36m.
jtocrr.org/article/S2666-…